Dual inhibition of ras and bcr-abl signalling pathways in chronic myeloid leukaemia: a phase I/II study in patients in complete haematological remission.

about

Dual inhibition of ras and bcr-abl signalling pathways in chronic myeloid leukaemia: a phase I/II study in patients in complete haematological remission.

Item

http://www.wikidata.org/entity/Q40452878

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Dual inhibition of ras and bcr ...... lete haematological remission.

@en

type

Item

label

Dual inhibition of ras and bcr ...... lete haematological remission.

@en

prefLabel

Dual inhibition of ras and bcr ...... lete haematological remission.

@en

P1476

Dual inhibition of ras and bcr ...... lete haematological remission.

@en

P2093

Catharina Andreasson

http://www.w3.org/2001/XMLSchema#string

Charles Chuah

http://www.w3.org/2001/XMLSchema#string

David Marin

http://www.w3.org/2001/XMLSchema#string

Jane F Apperley

http://www.w3.org/2001/XMLSchema#string

Jaspal Kaeda

http://www.w3.org/2001/XMLSchema#string

Jiri Pavlu

http://www.w3.org/2001/XMLSchema#string

John M Goldman

http://www.w3.org/2001/XMLSchema#string

P2860

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

Chronic myeloid leukemia--advances in biology and new approaches to treatment.

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.

A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease.

The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate.

Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases.

Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases.

Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.

Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial

P304

423-428

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2141.2007.06578.X

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

137

http://www.w3.org/2001/XMLSchema#string

P577

2007-04-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51392063

http://www.w3.org/2001/XMLSchema#string

P698

17428238

http://www.w3.org/2001/XMLSchema#string

P921

leukemia